Business Context and Reporting Period
This Form 8-K Current Report was filed by Krystal Biotech, Inc. on March 6, 2023. The filing reports a corporate governance event regarding the expansion of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial statement data.
Material Changes
The Board of Directors approved an increase in the size of the Board from eight (8) to nine (9) directors. Catherine Mazzacco was appointed as an independent member to fill the vacancy created by this expansion.
Outlook, Commentary, and Risks
- Appointment Details: Ms. Mazzacco will serve as a Class I director and stand for election at the 2024 annual meeting. She will serve on the Nominating and Corporate Governance committee.
- Background: Ms. Mazzacco previously served as CEO & President of LEO Pharma (2019-2021), Senior Vice President at GE HealthCare (2018-2019), and held various leadership roles at Abbott Laboratories for over 25 years.
- Compensation and Agreements: As a non-employee director, she will receive compensation consistent with the Company's definitive proxy statement filed on April 7, 2022. An indemnification agreement on standard terms has been executed.
- Conflicts of Interest: The filing states there are no arrangements or transactions requiring reporting under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the specific compensation amounts for non-employee directors in the definitive proxy statement filed on April 7, 2022.
- Review the press release attached as Exhibit 99.1 for additional context on the appointment.
- Confirm the terms of the indemnification agreement referenced in the Company's 2022 Form 10-K (Exhibit 10.1).